Home » Topics » BioWorld Science, Respiratory

BioWorld Science, Respiratory
RSS

Acticor initiates phase II trial of glenzocimab to treat COVID-19 related ARDS

Dec. 23, 2020

SOURCE trial of tezepelumab in severe asthma misses primary endpoint

Dec. 23, 2020

Chiesi Farmaceutici divulges new P2X3 receptor antagonists

Dec. 21, 2020

Interim analysis update on remestemcel-L study in COVID-19 ARDS

Dec. 21, 2020

New hMPV-derived vaccines presented by Valneva

Dec. 18, 2020

Vasomune initiates first-in-human study of AV-001 as potential therapy for COVID-19 and ARDS

Dec. 18, 2020

New phase III trial evaluates siltuximab for COVID-19 or viral-associated ARDS

Dec. 17, 2020

European Commission approves Trixeo Aerosphere for maintenance treatment of COPD

Dec. 15, 2020

New preclinical data confirms efficacy of apelin agonists in ARDS

Dec. 10, 2020

Lyra Therapeutics presents positive data from phase II LANTERN study of LYR-210

Dec. 9, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...